

NOVEL APPLICATIONS FOR VACCINE DELIVERY UTILIZING BLOW/FILL/SEAL TECHNOLOGY

SOLVING PROBLEMS WITH BFS PACKAGING

DCVMN AGM SÃO PAULO OCTOBER 2024





Matthew Peters Global Health Labs, Inc. Rommelag

Tim Kram




OPTIMIZING VACCINE LOGISTICS IN DEVELOPING COUNTRIES — VACCINE PACKAGING SOLUTIONS

- Introductions
- *Logistics* challenges with glass packaging of vaccines
 - Distribution, cold chain space, wastage
 - Manufacturing
- Plastic packaging solutions
- Commercial Blow Fill Seal (BFS) processes to deliver these solutions
- BFS process how does it work
- De-risking BFS processes for use with vaccines
- Next steps

FOLDING MULTI-MONODOSE (MMD) AMPOULES

Folding single-dose ampoules reduce cold chain space to multi-dose levels







folded ampoule card



Vaccine	Doses per vial	(cm³/dose)
DTP-HepB (Serum Institute)	20	2.1
IPV (Imovax)	10	2.4
IPV (Serum Institute)	10	3.4
PCV-13 (Prevnar 13)	4	3.5
BFS Ampoules (foil pack of 5 single doses)	1	~3
PCV-13 (Prevnar 13)	1	12
Rota (Rotarix)	5	12
IPV (IPV Vaccine SSI)	1	12.9
DTP-HepB-HI (Serum Institute)	1	14
HPV (Gardasil)	1	15
Rota (Rotarix)	1	17


BFS PROCESS AND BENEFITS

- Blow Fill Seal (BFS) Process
- Simple process Inputs to BFS machine are plastic pellets (LDPE) and bulk vaccine bulk
- Systems are sterile, GMP, and BSL2
- Well established with WFI and other pharma products (including some vaccines), leachables understood
- Molds to form ampoules are readily modified to specific needs of vaccines
- Capital costs are comparable, if not better, than glass packaging
- Operation costs are lower than glass packaging

OPTIMIZING BFS FOR VACCINE TESTING (AND MANUFACTURING)

BFS machine in Switzerland available for TEST FILLING vaccines:

- Hardware (e.g. molds) for BFS machine in GMP/BSL2 facility capable of producing material suitable for use in clinical trials
- Front end optimized to test laboratory batches of bulk vaccine as small as 1 L
- Optimized CoolBFS multiple layers of cooling systems added to remove all process heat exposure to vaccines
- Product flow through system optimized to maintain adjuvant suspensions during fill



WORLD-WIDE PRESENCE





Presentation Topic • 2025-05-22

ROMMELAG CMO



BSL-2 FACILITY ZELL SWITZERLAND

- 2012 opening
- Modular design:
 - Module 0 base function
 - Module 1 test BFS unit
 - Module 2 and 3 ready to build expansions
- Validated for biologics and vaccines
- Small batch capability
- Disposables option (filling system)
- Open facility design



• 20 • 7





Presentation Topic · 2025-05-22 · 8


LINKS TO VIDEO



- Company general-
- https://www.rommelag.com/en/technologies/blow-fill-seal
- 321M BFS machines showing individual systems -
- https://www.youtube.com/watch?v=PNN69NxT3Oc
- **Rotary BFS technology**
- https://www.youtube.com/watch?v=K7awm57wgiY
- https://www.youtube.com/watch?v=djYqnMipKS8

CONCLUSIONS AND NEXT STEPS

- BFS process is ready to package vaccines
- New Horizons and Rommelag will continue to develop packaging concepts for more off-the-shelf packaging solutions – direct injection, drop size regulation, etc.
- In field trials of packaging designs will continue
- There may be funding available to support trial fills
- Reach out to Tim Kram for more information







Testing water-filled NH BFS ampoules in Uganda.
Photos from BMGF-funded PATH report
"Programmatic and human factors evaluation of
three blow-fill-seal parenteral vaccine container
designs" submitted to Rommelag March 2018

THANK YOU -- QUESTIONS?

Dr. Matt Peters

- New Horizons a Division of Global
 Engineer/Business Development **Health Labs**
- Nonprofit fully funded by Gates **Ventures**
- Engineer/Business Development
- Leads several projects to solve vaccine delivery problems in LMIC
- mpeters@nhgh.org

Tim Kram

- Managing Director, Rommelag USA
- Projects to test and manufacture vaccines with Blow/Fill/Seal technology
- Company representative to the **DCVMN**
- Tim.Kram@rommelag.com

INTRODUCTIONS – MATTHEW PETERS

- New Horizons a Division of Global Health Labs
- Nonprofit fully funded by Gates Ventures
- Engineer/Business Development
- Leads several projects to solve vaccine delivery problems in LMIC
- mpeters@nhgh.org

INTRODUCTIONS – TIM KRAM

- Rommelag USA
- Managing Director

• Tim.Kram@rommelag.com

GLASS VACCINE PACKAGING ISSUES (IN DEVELOPING COUNTRIES)

- Vaccine distribution logistics issues:
 - Cold chain space
 - Wastage
 - Counterfeiting
- Manufacturing logistics:
 - Raw material supply chain
 - Local manufacturing difficult or not possible
 - Lessons from COVID-19 vaccines





Cold box vaccine transfer (Nepal)



State vaccine store (Nigeria)



Off-grid clinic (DRC)



Outreach (Syria, India)

COLD CHAIN STORAGE SPACE

- Vaccine distribution systems are stressed
 - Cold chain equipment is expensive
 - A lot of the equipment functions poorly
 - More vaccine doses needed as populations grow
 - More vaccine types are being added (e.g. HPV, COVID, RSV)
- Multi-dose glass vials help, but introduce new problems (e.g. wastage)
- Routine vaccines may one day be out of the cold chain (due to reformulation, use microarray patches, etc.) but that day is still far away

Rotarix vaccines take up most of the space in this refrigerator the only one in this Kenyan clinic.





Cholera vaccine campaign staff in Bangladesh sacrifice icepacks for vaccines to accommodate 11 mL/dose packaging

Vaccine Cold Chain Volumes in Secondary Packaging per WHO (https://extranet.who.int/pqweb/vaccines/prequalified-vaccines)

Vaccine	Doses per vial	(cm³/dose)
DTP-HepB (Serum Institute)	20	2.1
IPV (Imovax)	10	2.4
IPV (Serum Institute)	10	3.4
PCV-13 (Prevnar 13)	4	3.5
PCV-13 (Prevnar 13)	1	12
Rota (Rotarix)	5	12
IPV (IPV Vaccine SSI)	1	12.9
DTP-HepB-HI (Serum Institute)	1	14
HPV (Gardasil)	1	15
Rota (Rotarix)	1	17

WASTAGE IN MULTI-DOSE VIALS

- Once tapped, most multi-dose containers can only be used for a few hours before remaining vaccine must be discarded
- Cold chain space savings from multi-dose vials is substantially offset by high wastage



Multi-dose RI vaccine vials in a clinic in Nairobi, Kenya.

Vaccine wastage numbers WHO uses for coverage planning		
Vial presentation	Routine	Campaigns
Single Dose	5%	5%
2 or 5-dose, regardless of MDVP	10%	10%
10 or 20-dose: if opened vial can be re-used in subsequent sessions	25%	15%
10 or 20-dose: if opened vial must be discarded at end of session or maximum in 6 hours from the time the vial was opened	40%	15%
20-dose or more: if opened vial must be discarded at end of session	50%	20%
From WHO April 8, 2019 Concept Note: https://www.wsource/immunization/tools/revising-wastage-concept-n		

SE NEWS

June 6, 2022, 1:27 AM PDT

The U.S. has wasted over 82 million Covid vaccine doses

Vaccine providers say declining demand, large minimum orders and multidose vials make it hard to avoid waste while still offering shots to anyone who wants them.

Sept. 23, 2021, 1:30 AM PD By Joshua Eaton

The U.S. is discarding millions of Covid vaccines. One cause: Multi-dose vials.

The federal government is working with Covid-19 vaccine manufacturers to reduce the number of doses per vial, amid growing concerns about wasted vaccines.

COUNTERFEITING VACCINES IN GLASS VIALS





Indian police investigate whether scammers gave thousands of shots of salt water instead of vaccine.

Fourteen people have been charged with conspiracy and forgery, the latest example of fraud undermining India's pandemic response.

The New York Times





"An estimated 1 in 10 medical products in low- and middle-income countries is substandard or falsified."

GLASS SUPPLY CHAIN AND MANUFACTURING COMPLEXITY

Bloomberg

By Riley Griffin
June 25, 2020 at 2:00 AM PDT

Fear of Vial Shortage for Covid Vaccines Prompts Flurry of Deals

- CEPI secures production for 100 million multidose glass vials
- Move follows similar deals made by companies, U.S. government

The Telegraph

By Sarah Newey, GLOBAL HEALTH SECURITY CORRESPONDENT
19 January 2022 • 10:49am

Plastic pouches to replace glass vials as Covid vaccine manufacturing ramps up in Africa

The Institut Pasteur de Dakar aims to produce 300m doses a year, and will use plastic pouches to package the shots rather than glass vials

NON-GLASS PACKAGING INNOVATIONS — SOLVING PROBLEMS WITH AMPOULE DESIGNS

- The work shown here is a set of PROOF of CONCEPT designs to address critical vaccine logistics issues associated with glass packaging
- Vaccine manufacturers can tweak designs as needed to solve other problems such as accessing vaccine contents, labeling needs, etc.
- Blow Fill Seal process allows these designs and others to be readily produced (i.e. cost effective)



The initial design concept for this work functions like a standard glass ampoule




BFS COOLING TO PROCESS VACCINES IS NOW VALIDATED



5 L bulk tanks supports small volume test fills down to 1 L of product and is jacketed for product cooling. Transfer lines to filling machine are insulated to retain cooling.






No cooling on machine

Hottest spot - 65°C


Filling mandrels Ampoule mold set

Punch tool



Tank, filling mandrels, mold and punch tool cooling

Hottest spot - 61°C




Tank, filling mandrels, mold and punch tool cooling with post-fill cooling tunnel activated

Hottest spot - 25°C

After active cooling steps, ampoules continue to cool as they are held upright during transfer to the visual inspection and leak testing stations

MANAGING ADJUVANT SUSPENSIONS

- Product suspensions are maintained throughout the filling system and across all ampoule positions
- Light-transmission assay monitors suspension behavior in real time at plant to make corrections during the fill if needed



VACCINE TRIALS TO DATE

- Live attenuated flu vaccine nasal spray
- Multiple oral rotavirus vaccine products
- RSV vaccine
- Conjugated vaccines
- 2 more VVM 2 vaccines...

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*

Eric A. Sheldon,^a Robert Jeanfreau,^b Joseph A. Sliman,^{c,†} Supoat Charenkavanich,^{d,†} Matthew D. Rousculp,^{e,†} Filip Dubovsky,^f Raburn M. Mallory^f

^aRheumatology and Internal Medicine, Miami Research Associates, Miami, FL, USA. ^bInternal Medicine, Benchmark Research, Metairie, LA, USA. ^cVanda Pharmaceuticals, Inc., Washington, DC, USA. ^di3Statprobe, Clarksburg, MD, USA. ^cComparative Effectiveness Research, GlaxoSmithKline, Research Triangle Park, NC, USA. ^fClinical Development, MedImmune, LLC, Gaithersburg, MD, USA.

Correspondence: Raburn M. Mallory, Clinical Development, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. E-mail: malloryr@medimmune.com

*Previous presentation: Data from this study were presented at the 48th Annual Meeting of the Infectious Diseases Society of America, October 21–24, 2010, Vancouver, British Columbia, Canada (Abstract No. 3671).

†At the time this study was conducted, Drs. Sliman, Charenkavanich, and Rousculp were employees of MedImmune, LLC, Gaithersburg, MD

Trial registration: Clinicaltrials.gov identifier NCT00952705.

Accepted 08 September 2012. Published Online 14 October 2012.



AMPOULE CARD FOLDING MACHINE

Mechanized folding is a key component for mass-producible reduced-volume vaccine packaging process



unfolded ampoule card





folded ampoule card

Tolded ampoule card

Picker folds 5-ampoule card and secures to transfer to pouching feed line

Ampoule folding picker arm unit:

- Grabs an unfolded card of 5 ampoules from one processing line
- Folds it
- Transfers folded ampoule card to the flow wrapper feed line

Ampoules are then held in folded state by rails as they proceed to flow wrapper/foil-pouching machine



Folded 5-ampoule card is transferred to flow wrapper feed line



Rails on flow wrapper feed line maintain folded state until fully foil-pouched

SECONDARY PACKAGING

Secondary packaging solutions

- Labeling and VVM
- Needs product to drive regulatory discussions with WHO
- Clarity on labeling could reduce packaging size
- Overwrap and boxes lock in cold chain space savings





